Inhibikase Therapeutics, Inc. (IKT) vs Century Therapeutics, Inc. (IPSC)
A side-by-side comparison of Inhibikase Therapeutics, Inc. and Century Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IKT
Inhibikase Therapeutics, Inc.
$1.98HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
IPSC
Century Therapeutics, Inc.
$1.32HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — IKT vs IPSC
growth of $100 · dividends reinvested · last 5yIKT -88.5% (-35.1%/yr)IPSC -93.5% (-42.1%/yr)IKT compounded faster over this window
IKT IPSC
IKT vs IPSC: by the numbers
- •IKT is the larger company ($261M vs $239M market cap).
- •Both run net losses; IKT's is the smaller (0.00% vs -8.78% net margin).
Metrics side by side
Valuation
| Metric | IKT | IPSC |
|---|---|---|
| P/B ratio | 1.71 | 1.03 |
Profitability
| Metric | IKT | IPSC |
|---|---|---|
| Gross margin | 0.00% | 88.00% |
| Operating margin | 0.00% | -13.78% |
| Net margin | 0.00% | -8.78% |
| ROE | -39.55% | -47.25% |
| ROIC | -42.92% | -43.69% |
Growth (annualized)
| Metric | IKT | IPSC |
|---|---|---|
| Total return CAGR (5Y) | -29.10% | -42.05% |
Frequently asked
- How have IKT and IPSC total returns compared?
- Over the past 5 years, IKT delivered -29.10% and IPSC delivered -42.05% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.